Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1995 10
1996 15
1997 15
1998 17
1999 33
2000 35
2001 53
2002 80
2003 66
2004 77
2005 86
2006 72
2007 82
2008 108
2009 132
2010 134
2011 143
2012 136
2013 153
2014 148
2015 147
2016 151
2017 120
2018 115
2019 114
2020 114
2021 65
Text availability
Article attribute
Article type
Publication date

Search Results

2,210 results
Results by year
Filters applied: . Clear all
Page 1
Multiple Sclerosis.
Reich DS, Lucchinetti CF, Calabresi PA. Reich DS, et al. N Engl J Med. 2018 Jan 11;378(2):169-180. doi: 10.1056/NEJMra1401483. N Engl J Med. 2018. PMID: 29320652 Free PMC article. Review. No abstract available.
Pregnancy and Family Planning in Multiple Sclerosis.
Langer-Gould AM. Langer-Gould AM. Continuum (Minneap Minn). 2019 Jun;25(3):773-792. doi: 10.1212/CON.0000000000000745. Continuum (Minneap Minn). 2019. PMID: 31162316 Review.
RECENT FINDINGS: Recent studies indicate that most women diagnosed with MS today can have children, breast-feed, and resume beta interferons or glatiramer acetate per their preferences without incurring an increased risk of relapses during the postpartum period. ... …
RECENT FINDINGS: Recent studies indicate that most women diagnosed with MS today can have children, breast-feed, and resume beta interferons …
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N; MSBase Study Group. Brown JWL, et al. JAMA. 2019 Jan 15;321(2):175-187. doi: 10.1001/jama.2018.20588. JAMA. 2019. PMID: 30644981 Free PMC article.
EXPOSURES: The use, type, and timing of the following DMTs: interferon beta, glatiramer acetate, fingolimod, natalizumab, or alemtuzumab. After propensity-score matching, 1555 patients were included (last follow-up, February 14, 2017). ...The probability of conversi …
EXPOSURES: The use, type, and timing of the following DMTs: interferon beta, glatiramer acetate, fingolimod, natalizumab, or a …
Glatiramer acetate: A complex drug beyond biologics.
Rocco P, Eberini I, Musazzi UM, Franzè S, Minghetti P. Rocco P, et al. Eur J Pharm Sci. 2019 May 15;133:8-14. doi: 10.1016/j.ejps.2019.03.011. Epub 2019 Mar 19. Eur J Pharm Sci. 2019. PMID: 30902653 Free article. Review.
In the case of Non Biological Complex Drugs (NBCDs), complexity may arise either from the active substance, as in the case of glatiramer acetate, or from other sources, such as the formulation, as in the case of liposomes. In this paper, the case of glatiramer
In the case of Non Biological Complex Drugs (NBCDs), complexity may arise either from the active substance, as in the case of glatiramer
Highly Aggressive Multiple Sclerosis.
Bowen JD. Bowen JD. Continuum (Minneap Minn). 2019 Jun;25(3):689-714. doi: 10.1212/CON.0000000000000731. Continuum (Minneap Minn). 2019. PMID: 31162312 Review.
Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis: A meta-analysis.
Landmeyer NC, Bürkner PC, Wiendl H, Ruck T, Hartung HP, Holling H, Meuth SG, Johnen A. Landmeyer NC, et al. Neurology. 2020 Jun 2;94(22):e2373-e2383. doi: 10.1212/WNL.0000000000009522. Epub 2020 May 19. Neurology. 2020. PMID: 32430312
Twenty-five studies were related to platform therapies (mainly beta-interferon [n = 17] and glatiramer acetate [n = 4]), whereas 22 studies were related to escalation therapies (mainly natalizumab [n = 14] and fingolimod [n = 6]). ...
Twenty-five studies were related to platform therapies (mainly beta-interferon [n = 17] and glatiramer acetate [n = 4]), where …
Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
Cohen J, Belova A, Selmaj K, Wolf C, Sormani MP, Oberyé J, van den Tweel E, Mulder R, Koper N, Voortman G, Barkhof F; Glatiramer Acetate Clinical Trial to Assess Equivalence With Copaxone (GATE) Study Group. Cohen J, et al. JAMA Neurol. 2015 Dec;72(12):1433-41. doi: 10.1001/jamaneurol.2015.2154. JAMA Neurol. 2015. PMID: 26458034 Clinical Trial.
IMPORTANCE: The patents for the first approved treatments for relapsing-remitting multiple sclerosis are expiring, creating the opportunity to develop generic alternatives. OBJECTIVE: To evaluate in the Glatiramer Acetate Clinical Trial to Assess Equivalence With Co …
IMPORTANCE: The patents for the first approved treatments for relapsing-remitting multiple sclerosis are expiring, creating the opportunity …
Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A. La Mantia L, et al. Cochrane Database Syst Rev. 2016 Nov 24;11(11):CD009333. doi: 10.1002/14651858.CD009333.pub3. Cochrane Database Syst Rev. 2016. PMID: 27880972 Free PMC article. Review.
BACKGROUND: Interferons-beta (IFNs-beta) and glatiramer acetate (GA) were the first two disease-modifying therapies (DMTs) approved 20 years ago for the treatment of multiple sclerosis (MS). ...The purpose of this systematic review is to summarise available evidence …
BACKGROUND: Interferons-beta (IFNs-beta) and glatiramer acetate (GA) were the first two disease-modifying therapies (DMTs) app …
2,210 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page